Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 376

1.

Correction to Brønsted-Acid-Promoted Rh-Catalyzed Asymmetric Hydrogenation of N-Unprotected Indoles: A Cocatalysis of Transition Metal and Anion Binding.

Wen J, Fan X, Tan R, Chien HC, Zhou Q, Chung LW, Zhang X.

Org Lett. 2018 Jul 20;20(14):4390. doi: 10.1021/acs.orglett.8b01912. Epub 2018 Jul 9. No abstract available.

PMID:
29984575
2.

Silicon-oriented regio- and enantioselective rhodium-catalyzed hydroformylation.

You C, Li X, Yang Y, Yang YS, Tan X, Li S, Wei B, Lv H, Chung LW, Zhang X.

Nat Commun. 2018 May 23;9(1):2045. doi: 10.1038/s41467-018-04277-7.

3.

Matrilysin/MMP-7 Cleavage of Perlecan/HSPG2 Complexed with Semaphorin 3A Supports FAK-Mediated Stromal Invasion by Prostate Cancer Cells.

Grindel BJ, Martinez JR, Tellman TV, Harrington DA, Zafar H, Nakhleh L, Chung LW, Farach-Carson MC.

Sci Rep. 2018 May 8;8(1):7262. doi: 10.1038/s41598-018-25435-3.

4.

Rhodium-catalyzed asymmetric hydrogenation of β-cyanocinnamic esters with the assistance of a single hydrogen bond in a precise position.

Li X, You C, Yang Y, Yang Y, Li P, Gu G, Chung LW, Lv H, Zhang X.

Chem Sci. 2018 Jan 4;9(7):1919-1924. doi: 10.1039/c7sc04639a. eCollection 2018 Feb 21.

5.

Catalytic asymmetric trifluoromethylthiolation of carbonyl compounds via a diastereo and enantioselective Cu-catalyzed tandem reaction.

Jin MY, Li J, Huang R, Zhou Y, Chung LW, Wang JJ.

Chem Commun (Camb). 2018 May 1;54(36):4581-4584. doi: 10.1039/c8cc02097c.

PMID:
29667658
6.

Structure and function analysis in circulating tumor cells: using nanotechnology to study nuclear size in prostate cancer.

Yao N, Jan YJ, Cheng S, Chen JF, Chung LW, Tseng HR, Posadas EM.

Am J Clin Exp Urol. 2018 Apr 1;6(2):43-54. eCollection 2018. Review.

7.

Dr. Coffey's visionary contributions to urological research in China and Japan.

Shimazaki J, Chung LW, Zhau HE, Ichikawa T.

Am J Clin Exp Urol. 2018 Apr 1;6(2):15-22. eCollection 2018. No abstract available.

8.

Design and Application of Hybrid Phosphorus Ligands for Enantioselective Rh-Catalyzed Anti-Markovnikov Hydroformylation of Unfunctionalized 1,1-Disubstituted Alkenes.

You C, Li S, Li X, Lan J, Yang Y, Chung LW, Lv H, Zhang X.

J Am Chem Soc. 2018 Apr 18;140(15):4977-4981. doi: 10.1021/jacs.8b00275. Epub 2018 Apr 4.

PMID:
29601724
9.

Brønsted-Acid-Promoted Rh-Catalyzed Asymmetric Hydrogenation of N-Unprotected Indoles: A Cocatalysis of Transition Metal and Anion Binding.

Wen J, Fan X, Tan R, Chien HC, Zhou Q, Chung LW, Zhang X.

Org Lett. 2018 Apr 20;20(8):2143-2147. doi: 10.1021/acs.orglett.8b00312. Epub 2018 Mar 30. Erratum in: Org Lett. 2018 Jul 20;20(14):4390.

PMID:
29600702
10.

Development of a novel secondary phosphine oxide-ruthenium(ii) catalyst and its application for carbonyl reduction.

Tan X, Zeng W, Zhang X, Chung LW, Zhang X.

Chem Commun (Camb). 2018 Jan 11;54(5):535-538. doi: 10.1039/c7cc07647a. Erratum in: Chem Commun (Camb). 2018 May 9;:.

PMID:
29271428
11.

Nickel-catalyzed asymmetric hydrogenation of β-acylamino nitroolefins: an efficient approach to chiral amines.

Gao W, Lv H, Zhang T, Yang Y, Chung LW, Wu YD, Zhang X.

Chem Sci. 2017 Sep 1;8(9):6419-false. doi: 10.1039/c7sc02669b. Epub 2017 Jul 4.

12.

Modulation of cabozantinib efficacy by the prostate tumor microenvironment.

Tripathi M, Nandana S, Billet S, Cavassani KA, Mishra R, Chung LWK, Posadas EM, Bhowmick NA.

Oncotarget. 2017 Sep 23;8(50):87891-87902. doi: 10.18632/oncotarget.21248. eCollection 2017 Oct 20.

13.

Computational Prediction of Excited-State Carbon Tunneling in the Two Steps of Triplet Zimmerman Di-π-Methane Rearrangement.

Li X, Liao T, Chung LW.

J Am Chem Soc. 2017 Nov 22;139(46):16438-16441. doi: 10.1021/jacs.7b07539. Epub 2017 Nov 9.

PMID:
29037035
14.

Efficient syntheses of (-)-crinine and (-)-aspidospermidine, and the formal synthesis of (-)-minfiensine by enantioselective intramolecular dearomative cyclization.

Du K, Yang H, Guo P, Feng L, Xu G, Zhou Q, Chung LW, Tang W.

Chem Sci. 2017 Sep 1;8(9):6247-6256. doi: 10.1039/c7sc01859b. Epub 2017 Jul 3.

15.

Enantioselective palladium-catalyzed diboration of 1,1-disubstituted allenes.

Liu J, Nie M, Zhou Q, Gao S, Jiang W, Chung LW, Tang W, Ding K.

Chem Sci. 2017 Jul 1;8(7):5161-5165. doi: 10.1039/c7sc01254c. Epub 2017 May 16.

16.

Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression.

Ren S, Wei GH, Liu D, Wang L, Hou Y, Zhu S, Peng L, Zhang Q, Cheng Y, Su H, Zhou X, Zhang J, Li F, Zheng H, Zhao Z, Yin C, He Z, Gao X, Zhau HE, Chu CY, Wu JB, Collins C, Volik SV, Bell R, Huang J, Wu K, Xu D, Ye D, Yu Y, Zhu L, Qiao M, Lee HM, Yang Y, Zhu Y, Shi X, Chen R, Wang Y, Xu W, Cheng Y, Xu C, Gao X, Zhou T, Yang B, Hou J, Liu L, Zhang Z, Zhu Y, Qin C, Shao P, Pang J, Chung LWK, Xu J, Wu CL, Zhong W, Xu X, Li Y, Zhang X, Wang J, Yang H, Wang J, Huang H, Sun Y.

Eur Urol. 2017 Sep 18. pii: S0302-2838(17)30720-0. doi: 10.1016/j.eururo.2017.08.027. [Epub ahead of print]

PMID:
28927585
17.

Reactive oxygen species-mediated switching expression of MMP-3 in stromal fibroblasts and cancer cells during prostate cancer progression.

Hsieh CL, Liu CM, Chen HA, Yang ST, Shigemura K, Kitagawa K, Yamamichi F, Fujisawa M, Liu YR, Lee WH, Chen KC, Shen CN, Lin CC, Chung LWK, Sung SY.

Sci Rep. 2017 Aug 22;7(1):9065. doi: 10.1038/s41598-017-08835-9.

18.

Practical and Asymmetric Reductive Coupling of Isoquinolines Templated by Chiral Diborons.

Chen D, Xu G, Zhou Q, Chung LW, Tang W.

J Am Chem Soc. 2017 Jul 26;139(29):9767-9770. doi: 10.1021/jacs.7b04256. Epub 2017 Jul 14.

PMID:
28700227
19.

Erratum: Organocatalytic atroposelective synthesis of axially chiral styrenes.

Zheng SC, Wu S, Zhou Q, Chung LW, Ye L, Tan B.

Nat Commun. 2017 Jun 27;8:16119. doi: 10.1038/ncomms16119.

20.

Ferrocenyl chiral bisphosphorus ligands for highly enantioselective asymmetric hydrogenation via noncovalent ion pair interaction.

Chen C, Wang H, Zhang Z, Jin S, Wen S, Ji J, Chung LW, Dong XQ, Zhang X.

Chem Sci. 2016 Nov 1;7(11):6669-6673. doi: 10.1039/c6sc01845a. Epub 2016 Jun 30.

21.

Reaction Mechanism of Cu(I)-Mediated Reductive CO2 Coupling for the Selective Formation of Oxalate: Cooperative CO2 Reduction To Give Mixed-Valence Cu2(CO2•-) and Nucleophilic-Like Attack.

Lan J, Liao T, Zhang T, Chung LW.

Inorg Chem. 2017 Jun 19;56(12):6809-6819. doi: 10.1021/acs.inorgchem.6b03080. Epub 2017 May 30.

PMID:
28558249
22.

Enzyme-Inspired Chiral Secondary-Phosphine-Oxide Ligand with Dual Noncovalent Interactions for Asymmetric Hydrogenation.

Chen C, Zhang Z, Jin S, Fan X, Geng M, Zhou Y, Wen S, Wang X, Chung LW, Dong XQ, Zhang X.

Angew Chem Int Ed Engl. 2017 Jun 6;56(24):6808-6812. doi: 10.1002/anie.201701394. Epub 2017 May 11.

PMID:
28493501
23.

Organocatalytic atroposelective synthesis of axially chiral styrenes.

Zheng SC, Wu S, Zhou Q, Chung LW, Ye L, Tan B.

Nat Commun. 2017 May 3;8:15238. doi: 10.1038/ncomms15238. Erratum in: Nat Commun. 2017 Jun 27;8:16119.

24.

Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.

Recouvreux MV, Wu JB, Gao AC, Zonis S, Chesnokova V, Bhowmick N, Chung LW, Melmed S.

Endocrinology. 2017 Jul 1;158(7):2255-2268. doi: 10.1210/en.2016-1939.

25.

Upregulation of minichromosome maintenance complex component 3 during epithelial-to-mesenchymal transition in human prostate cancer.

Stewart PA, Khamis ZI, Zhau HE, Duan P, Li Q, Chung LWK, Sang QA.

Oncotarget. 2017 Jun 13;8(24):39209-39217. doi: 10.18632/oncotarget.16835.

26.

MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network Promotes Prostate Cancer Metastasis by Engaging Tumor-Stromal Cell Interactions.

Wu JB, Yin L, Shi C, Li Q, Duan P, Huang JM, Liu C, Wang F, Lewis M, Wang Y, Lin TP, Pan CC, Posadas EM, Zhau HE, Chung LWK.

Cancer Cell. 2017 Mar 13;31(3):368-382. doi: 10.1016/j.ccell.2017.02.003.

27.

Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis.

Nandana S, Tripathi M, Duan P, Chu CY, Mishra R, Liu C, Jin R, Yamashita H, Zayzafoon M, Bhowmick NA, Zhau HE, Matusik RJ, Chung LW.

Cancer Res. 2017 Mar 15;77(6):1331-1344. doi: 10.1158/0008-5472.CAN-16-0497. Epub 2017 Jan 20.

28.

Iridium-Catalyzed Asymmetric Hydrogenation of Ketones with Accessible and Modular Ferrocene-Based Amino-phosphine Acid (f-Ampha) Ligands.

Yu J, Long J, Yang Y, Wu W, Xue P, Chung LW, Dong XQ, Zhang X.

Org Lett. 2017 Feb 3;19(3):690-693. doi: 10.1021/acs.orglett.6b03862. Epub 2017 Jan 17.

PMID:
28093919
29.

Correction: Perlecan/HSPG2 and matrilysin/MMP-7 as indices of tissue invasion: tissue localization and circulating perlecan fragments in a cohort of 288 radical prostatectomy patients.

Grindel B, Li Q, Arnold R, Petros J, Zayzafoon M, Muldoon M, Stave J, Chung LW, Farach-Carson MC.

Oncotarget. 2016 Sep 13;7(37):60775. doi: 10.18632/oncotarget.11976. No abstract available.

30.

Guest-Induced Folding and Self-Assembly of Conformationally Adaptive Macrocycles into Nanosheets and Nanotubes.

Yang LP, Jia F, Zhou QH, Pan F, Sun JN, Rissanen K, Chung LW, Jiang W.

Chemistry. 2017 Jan 31;23(7):1516-1520. doi: 10.1002/chem.201605701. Epub 2017 Jan 11.

PMID:
28000968
31.

Alternative Mechanistic Strategy for Enzyme Catalysis in a Ni-Dependent Lactate Racemase (LarA): Intermediate Destabilization by the Cofactor.

Zhang X, Chung LW.

Chemistry. 2017 Mar 13;23(15):3623-3630. doi: 10.1002/chem.201604893. Epub 2016 Dec 16.

PMID:
27883243
32.

Keratin 13 expression reprograms bone and brain metastases of human prostate cancer cells.

Li Q, Yin L, Jones LW, Chu GC, Wu JB, Huang JM, Li Q, You S, Kim J, Lu YT, Mrdenovic S, Wang R, Freeman MR, Garraway I, Lewis MS, Chung LW, Zhau HE.

Oncotarget. 2016 Dec 20;7(51):84645-84657. doi: 10.18632/oncotarget.13175.

33.

Applications of circulating tumor cells for prostate cancer.

Cheng S, Chen JF, Lu YT, Chung LWK, Tseng HR, Posadas EM.

Asian J Urol. 2016 Oct;3(4):254-259. doi: 10.1016/j.ajur.2016.09.004. Epub 2016 Sep 14. Review.

34.

Cultured circulating tumor cells and their derived xenografts for personalized oncology.

Wang R, Chu GCY, Mrdenovic S, Annamalai AA, Hendifar AE, Nissen NN, Tomlinson JS, Lewis M, Palanisamy N, Tseng HR, Posadas EM, Freeman MR, Pandol SJ, Zhau HE, Chung LWK.

Asian J Urol. 2016 Oct;3(4):240-253. doi: 10.1016/j.ajur.2016.08.005. Epub 2016 Aug 25. Review.

35.

Biology and therapy of urological cancer metastasis.

Posadas EM, McConkey DJ, Chung LWK.

Asian J Urol. 2016 Oct;3(4):167-169. doi: 10.1016/j.ajur.2016.09.008. Epub 2016 Sep 23. No abstract available.

36.

Multiscale Simulations on Spectral Tuning and the Photoisomerization Mechanism in Fluorescent RNA Spinach.

Li X, Chung LW, Li G.

J Chem Theory Comput. 2016 Nov 8;12(11):5453-5464. Epub 2016 Oct 14.

PMID:
27685000
37.

Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients.

Liu S, Tian Z, Zhang L, Hou S, Hu S, Wu J, Jing Y, Sun H, Yu F, Zhao L, Wang R, Tseng HR, Zhau HE, Chung LW, Wu K, Wang H, Wu JB, Nie Y, Shao C.

Oncotarget. 2016 Sep 13;7(37):59877-59891. doi: 10.18632/oncotarget.10979.

38.

New Mechanistic Insights on the Selectivity of Transition-Metal-Catalyzed Organic Reactions: The Role of Computational Chemistry.

Zhang X, Chung LW, Wu YD.

Acc Chem Res. 2016 Jun 21;49(6):1302-10. doi: 10.1021/acs.accounts.6b00093. Epub 2016 Jun 7.

PMID:
27268125
39.

Co-Targeting Prostate Cancer Epithelium and Bone Stroma by Human Osteonectin-Promoter-Mediated Suicide Gene Therapy Effectively Inhibits Androgen-Independent Prostate Cancer Growth.

Sung SY, Chang JL, Chen KC, Yeh SD, Liu YR, Su YH, Hsueh CY, Chung LW, Hsieh CL.

PLoS One. 2016 Apr 7;11(4):e0153350. doi: 10.1371/journal.pone.0153350. eCollection 2016.

40.

Improving Therapeutic Potential of Farnesylthiosalicylic Acid: Tumor Specific Delivery via Conjugation with Heptamethine Cyanine Dye.

Guan Y, Zhang Y, Xiao L, Li J, Wang JP, Chordia MD, Liu ZQ, Chung LW, Yue W, Pan D.

Mol Pharm. 2017 Jan 3;14(1):1-13. doi: 10.1021/acs.molpharmaceut.5b00906. Epub 2016 Dec 16.

41.

Hydrogenation of Aldehydes Catalyzed by an Available Ruthenium Complex.

Tan X, Wang G, Zhu Z, Ren C, Zhou J, Lv H, Zhang X, Chung LW, Zhang L, Zhang X.

Org Lett. 2016 Apr 1;18(7):1518-21. doi: 10.1021/acs.orglett.6b00060. Epub 2016 Mar 14.

PMID:
26974348
42.

SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-Myc in prostate cancer.

Li X, Wu JB, Li Q, Shigemura K, Chung LW, Huang WC.

Oncotarget. 2016 Mar 15;7(11):12869-84. doi: 10.18632/oncotarget.7331.

43.

Perlecan/HSPG2 and matrilysin/MMP-7 as indices of tissue invasion: tissue localization and circulating perlecan fragments in a cohort of 288 radical prostatectomy patients.

Grindel B, Li Q, Arnold R, Petros J, Zayzafoon M, Muldoon M, Stave J, Chung LW, Farach-Carson MC.

Oncotarget. 2016 Mar 1;7(9):10433-47. doi: 10.18632/oncotarget.7197. Erratum in: Oncotarget. 2016 Sep 13;7(37):60775.

44.

Regulation of prostate cancer progression by the tumor microenvironment.

Shiao SL, Chu GC, Chung LW.

Cancer Lett. 2016 Sep 28;380(1):340-8. doi: 10.1016/j.canlet.2015.12.022. Epub 2016 Jan 28. Review.

45.

Prostate cancer metastasis: roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristics.

Ziaee S, Chu GC, Huang JM, Sieh S, Chung LW.

Transl Androl Urol. 2015 Aug;4(4):438-54. doi: 10.3978/j.issn.2223-4683.2015.04.10. Review.

46.

microRNAs and Prostate Cancer.

Josson S, Chung LW, Gururajan M.

Adv Exp Med Biol. 2015;889:105-18. doi: 10.1007/978-3-319-23730-5_7.

47.

SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.

Gururajan M, Cavassani KA, Sievert M, Duan P, Lichterman J, Huang JM, Smith B, You S, Nandana S, Chu GC, Mink S, Josson S, Liu C, Morello M, Jones LW, Kim J, Freeman MR, Bhowmick N, Zhau HE, Chung LW, Posadas EM.

Oncotarget. 2015 Dec 29;6(42):44072-83. doi: 10.18632/oncotarget.6398.

48.

A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer.

Jiang R, Lu YT, Ho H, Li B, Chen JF, Lin M, Li F, Wu K, Wu H, Lichterman J, Wan H, Lu CL, OuYang W, Ni M, Wang L, Li G, Lee T, Zhang X, Yang J, Rettig M, Chung LW, Yang H, Li KC, Hou Y, Tseng HR, Hou S, Xu X, Wang J, Posadas EM.

Oncotarget. 2015 Dec 29;6(42):44781-93. doi: 10.18632/oncotarget.6330.

49.

Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.

Li X, Wu JB, Chung LW, Huang WC.

Oncotarget. 2015 Dec 1;6(38):41018-32. doi: 10.18632/oncotarget.5879.

50.

Targeting the tumor-stromal-immune cell axis.

Gururajan M, Josson S, Chung LW.

Oncoscience. 2015 Aug 11;2(9):743-4. eCollection 2015. No abstract available.

Supplemental Content

Loading ...
Support Center